| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
|
Ou, Sai-Hong Ignatius
|
|
|
|
3 |
p.
|
artikel
|
| 2 |
Acknowledgment of Reviewers
|
|
|
|
|
3 |
p.
|
artikel
|
| 3 |
Acknowledgment of Reviewers
|
|
|
|
|
3 |
p.
|
artikel
|
| 4 |
Acknowledgment of Reviewers
|
|
|
|
|
3 |
p.
|
artikel
|
| 5 |
Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation
|
Joseph, Jacinth J.
|
|
|
|
3 |
p.
|
artikel
|
| 6 |
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
|
Fujino, Toshio
|
|
|
|
3 |
p.
|
artikel
|
| 7 |
A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation
|
Trabelsi-Grati, Olfa
|
|
|
|
3 |
p.
|
artikel
|
| 8 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, Po-Lan
|
|
|
|
3 |
p.
|
artikel
|
| 9 |
Anterior Mediastinal Amyloidosis Mimics Thymic Carcinoma
|
Ikeda, Satoshi
|
|
|
|
3 |
p.
|
artikel
|
| 10 |
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
|
Gainor, Justin F.
|
|
|
|
3 |
p.
|
artikel
|
| 11 |
Appendiceal Metastasis From Thymic Carcinoma: An Unusual Presentation of a Rare Cancer
|
Swift, Shannon
|
|
|
|
3 |
p.
|
artikel
|
| 12 |
Application of the Novel Grading System of Invasive Pulmonary Adenocarcinoma in a Real Diagnostic Scenario: A Brief Report of 9353 Cases
|
She, Yunlang
|
|
|
|
3 |
p.
|
artikel
|
| 13 |
A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern
|
Kerrigan, Kathleen
|
|
|
|
3 |
p.
|
artikel
|
| 14 |
A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019
|
Peravali, Monica
|
|
|
|
3 |
p.
|
artikel
|
| 15 |
Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC
|
Varlotto, John M.
|
|
|
|
3 |
p.
|
artikel
|
| 16 |
Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study
|
Bruno, Debora S.
|
|
|
|
3 |
p.
|
artikel
|
| 17 |
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
|
Karachaliou, Niki
|
|
|
|
3 |
p.
|
artikel
|
| 18 |
Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria—Reducing Race Disparities
|
Pasquinelli, Mary M.
|
|
|
|
3 |
p.
|
artikel
|
| 19 |
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
|
Smith, Clayton P.
|
|
|
|
3 |
p.
|
artikel
|
| 20 |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan, Daniel S.W.
|
|
|
|
3 |
p.
|
artikel
|
| 21 |
Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
|
Smith, Jarrod T.
|
|
|
|
3 |
p.
|
artikel
|
| 22 |
Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
|
Loong, Herbert H.
|
|
|
|
3 |
p.
|
artikel
|
| 23 |
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
|
Fujimoto, Nobukazu
|
|
|
|
3 |
p.
|
artikel
|
| 24 |
Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”
|
Yatabe, Yasushi
|
|
|
|
3 |
p.
|
artikel
|
| 25 |
Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
|
Katayama, Yuki
|
|
|
|
3 |
p.
|
artikel
|
| 26 |
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
|
Piper-Vallillo, Andrew J.
|
|
|
|
3 |
p.
|
artikel
|
| 27 |
Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin
|
Watanabe, Kageaki
|
|
|
|
3 |
p.
|
artikel
|
| 28 |
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
|
Miura, Satoru
|
|
|
|
3 |
p.
|
artikel
|
| 29 |
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
|
Cheung, Justin M.
|
|
|
|
3 |
p.
|
artikel
|
| 30 |
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
|
Yang, James Chih-Hsin
|
|
|
|
3 |
p.
|
artikel
|
| 31 |
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
|
Vasconcelos, Pedro E.N.S.
|
|
|
|
3 |
p.
|
artikel
|
| 32 |
EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
|
Lin, Huamao M.
|
|
|
|
3 |
p.
|
artikel
|
| 33 |
Erratum
|
|
|
|
|
3 |
p.
|
artikel
|
| 34 |
Gut Microbiota and Lung Cancer: A Mendelian Randomization Study
|
Zhou, Huaqiang
|
|
|
|
3 |
p.
|
artikel
|
| 35 |
Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC—RELANCE/LACOG 0118
|
Cordeiro de Lima, Vladmir C.
|
|
|
|
3 |
p.
|
artikel
|
| 36 |
Improvement in Stage of Lung Cancer Diagnosis With Incidental Pulmonary Nodules Followed With a Patient Tracking System and Computerized Registry
|
Carr, Laurie L.
|
|
|
|
3 |
p.
|
artikel
|
| 37 |
Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib
|
Teixeira, Carlos Henrique A.
|
|
|
|
3 |
p.
|
artikel
|
| 38 |
Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC
|
Khan, Farrah B.
|
|
|
|
3 |
p.
|
artikel
|
| 39 |
Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review
|
Sayani, Ambreen
|
|
|
|
3 |
p.
|
artikel
|
| 40 |
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
|
Ninomaru, Taira
|
|
|
|
3 |
p.
|
artikel
|
| 41 |
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
|
Teraoka, Shunsuke
|
|
|
|
3 |
p.
|
artikel
|
| 42 |
Long-Term Recurrence of Completely Resected NSCLC
|
Masago, Katsuhiro
|
|
|
|
3 |
p.
|
artikel
|
| 43 |
Lung Cancer Screening: An Opportunity to Promote Physical Activity?
|
Avancini, Alice
|
|
|
|
3 |
p.
|
artikel
|
| 44 |
Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
|
Moliner, Laura
|
|
|
|
3 |
p.
|
artikel
|
| 45 |
Not All EGFR Exon 20 Insertions Are Created Equal
|
Lin, Yen-Ting
|
|
|
|
3 |
p.
|
artikel
|
| 46 |
Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study
|
Chen, Donglai
|
|
|
|
3 |
p.
|
artikel
|
| 47 |
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
|
Ji, Jingran
|
|
|
|
3 |
p.
|
artikel
|
| 48 |
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
|
Ruppert, Anne-Marie
|
|
|
|
3 |
p.
|
artikel
|
| 49 |
Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital
|
Scagliotti, Giorgio
|
|
|
|
3 |
p.
|
artikel
|
| 50 |
Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
|
Vasconcelos, Pedro E.N.S.
|
|
|
|
3 |
p.
|
artikel
|
| 51 |
Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC
|
Komiya, Takefumi
|
|
|
|
3 |
p.
|
artikel
|
| 52 |
Rapid Onset of Takotsubo Cardiomyopathy Induced by an Infusion Reaction to Pembrolizumab in a Patient with NSCLC
|
Okamatsu, Yuki
|
|
|
|
3 |
p.
|
artikel
|
| 53 |
Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan
|
Yatabe, Yasushi
|
|
|
|
3 |
p.
|
artikel
|
| 54 |
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China
|
Fu, Rui
|
|
|
|
3 |
p.
|
artikel
|
| 55 |
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
|
Gibson, Amanda J.W.
|
|
|
|
3 |
p.
|
artikel
|
| 56 |
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
|
Osta, Badi El
|
|
|
|
3 |
p.
|
artikel
|
| 57 |
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
|
Remon, Jordi
|
|
|
|
3 |
p.
|
artikel
|
| 58 |
Successful Treatment of Nonbacterial Thrombotic Endocarditis and Disseminated Intravascular Coagulation in a Patient With Advanced Lung Adenocarcinoma Using Osimertinib
|
Shen, Hsiao-Chin
|
|
|
|
3 |
p.
|
artikel
|
| 59 |
Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC
|
Antonoff, Mara B.
|
|
|
|
3 |
p.
|
artikel
|
| 60 |
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
|
Vansteenkiste, Johan F.
|
|
|
|
3 |
p.
|
artikel
|
| 61 |
Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
|
Gerber, David E.
|
|
|
|
3 |
p.
|
artikel
|
| 62 |
The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities
|
Kale, Minal S.
|
|
|
|
3 |
p.
|
artikel
|
| 63 |
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
|
Kagawa, Yosuke
|
|
|
|
3 |
p.
|
artikel
|
| 64 |
The Feasibility and Safety of Routine Thoracic Surgeries in the Low-Risk Areas During the Coronavirus Disease 2019 Pandemic
|
Wang, Yiyang
|
|
|
|
3 |
p.
|
artikel
|
| 65 |
The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
|
Wong, Lye-Yeng
|
|
|
|
3 |
p.
|
artikel
|
| 66 |
The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
|
Salazar, Michelle C.
|
|
|
|
3 |
p.
|
artikel
|
| 67 |
Tracheobronchial and Pulmonary Amyloidosis Mimicking Pulmonary Metastases in a Patient With Lung Adenocarcinoma
|
Uematsu, Mao
|
|
|
|
3 |
p.
|
artikel
|
| 68 |
Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate
|
Arcila, Maria E.
|
|
|
|
3 |
p.
|
artikel
|
| 69 |
Unusual Resistance Mechanisms in a Case of ROS 1-Rearranged NSCLC: A Case Report
|
Batra, Ullas
|
|
|
|
3 |
p.
|
artikel
|
| 70 |
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
|
Negrao, Marcelo V.
|
|
|
|
3 |
p.
|
artikel
|
Tijdschrift beschrijving